The estimated Net Worth of Jeffrey H Cooper is at least $4.01 millió dollars as of 30 April 2012. Mr. Cooper owns over 25,250 units of Sierra Oncology Inc stock worth over $3,647,982 and over the last 20 years he sold SRRA stock worth over $361,136. In addition, he makes $0 as Independent Director at Sierra Oncology Inc.
Jeffrey has made over 32 trades of the Sierra Oncology Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 25,250 units of SRRA stock worth $591,103 on 30 April 2012.
The largest trade he's ever made was exercising 83,036 units of Sierra Oncology Inc stock on 24 February 2012 worth over $1,541,979. On average, Jeffrey trades about 9,861 units every 46 days since 2004. As of 30 April 2012 he still owns at least 66,339 units of Sierra Oncology Inc stock.
You can see the complete history of Mr. Cooper stock trades at the bottom of the page.
Jeffrey H. Cooper is an Independent Director of the Company. Mr. Cooper has served as an independent consultant for life sciences companies since January 2014. Previously, Mr. Cooper served at KaloBios Pharmaceuticals, Inc., a biotechnology company, as a senior advisor from November 2013 until December 2013 and as the Chief Financial Officer from July 2012 until October 2013. Prior to joining KaloBios, Mr. Cooper served in positions of increasing responsibility at BioMarin Pharmaceutical Inc., a pharmaceutical company, beginning as Vice President, Controller, to his most recent position as Senior Vice President and Chief Financial Officer from 2007 to May 2012. Mr. Cooper has also served as Vice President of Finance at Matrix Pharmaceutical, Inc. and held numerous finance-related positions within the health care and pharmaceutical industries, including Corporate Controller at Foundation Health Systems Inc. and Director of Business Analysis at Syntex Corporation. Mr. Cooper also previously served on the Board of Directors of Tobira Therapeutics, Inc. until it was acquired by Allergan plc in November 2016. Mr. Cooper received a B.A. from the University of California, Los Angeles and an M.B.A. from Santa Clara University. He is a Certified Public Accountant (inactive status) in the state of California. Our Board of Directors believes that Mr. Cooper should serve as a director based upon his experience as a senior executive in the life sciences industry, as well as his experience and skills relating to financial statement and accounting matters.
Jeffrey Cooper is 64, he's been the Independent Director of Sierra Oncology Inc since 2016. There are 3 older and 13 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.
Jeffrey's mailing address filed with the SEC is C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DR., SUITE 110, SAN MATEO, CA, 94404.
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth és James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Sierra Oncology Inc executives and other stock owners filed with the SEC include: